Company profile: Novira Therapeutics
1.1 - Company Overview
Company description
- Provider of antiviral drug discovery focused on first-in-class oral therapeutics targeting the viral capsid to treat chronic HBV and HIV infections, addressing diseases with high unmet need.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Novira Therapeutics
Aethlon Medical
HQ: United States
Website
- Description: Provider of immunotherapeutic technologies to combat infectious disease and cancer, including the Hemopurifier, a device designed to rapidly remove cancer-promoting exosomes and circulating viruses from the bloodstream, currently under clinical trials for various cancers and viral infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aethlon Medical company profile →
Paratek Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies based on novel tetracycline chemistry, including NUZYRA, an FDA-approved tetracycline-class antibiotic for adults with CABP and ABSSSI caused by select susceptible microorganisms, and SEYSARA, an FDA-approved oral therapy for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paratek Pharmaceuticals company profile →
Turn Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical solutions to reduce the human and economic costs of infection and skin disease, including PermaFusion petrolatum-based liquid-in-oil suspension technology for high-bioavailability delivery; Hexagen FDA-cleared antimicrobial wound dressing; a pre-operative nasal decolonization program targeting MRSA; and onychomycosis treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Turn Therapeutics company profile →
Daktari Diagnostics
HQ: United States
Website
- Description: Provider of diagnostic medical products for clinicians and patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Daktari Diagnostics company profile →
Vaxcyte
HQ: United States
Website
- Description: Provider of vaccines and vaccine development technologies, including VAX-24, a 24-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in adults (FDA Breakthrough Therapy); VAX-31, a 31-valent pneumococcal conjugate candidate; the XpressCF cell-free platform for site-specific conjugation to enhance immunogenicity; and preclinical programs for Group A Strep, periodontitis, and Shigella.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxcyte company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Novira Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Novira Therapeutics
2.2 - Growth funds investing in similar companies to Novira Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Novira Therapeutics
4.2 - Public trading comparable groups for Novira Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →